BAB, a consolidated subsidiary, obtained FDA 510(k) clearance for Accelagen\u2122 Plus Surgical Matrix, a private-brand product. Aiming to commence sales in the United States in Q1 2027, we are pursuing private-branding of the MedTech business. Minor impact on the consolidated results for the fiscal year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"GNI Group Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/2160-20260903-01.pdf","jir_short_summary":"BAB, a consolidated subsidiary, obtained FDA 510(k) clearance for Accelagen\u2122 Plus Surgical Matrix, a private-brand product. Aiming to commence sales in the United States in Q1 2027, we are pursuing private-branding of the MedTech business. Minor impact on the consolidated results for the fiscal year ending December 2026.","jir_summary":"### FDA approval of Accelagen Plus and business strategy\nConsolidated subsidiary BAB has obtained FDA 510(k) clearance for the first private-brand product Accelagen\u2122 Plus Surgical Matrix. By expanding the wound management portfolio with this new product, we will promote private-branding leveraging BAB's collagen and biomaterials technology. We aim to begin U.S. sales in Q1 2027, targeting profitability improvement and long-term growth of the MedTech business.\n\n### Upcoming sales launch and impact\nU.S. sales are scheduled to commence in Q1 2027. Expanding the private-brand framework including ACCELAGEN Plus will support profitability and long-term growth of the MedTech business. This approval is described as accelerating BAB's expansion into the wound management field.","jir_financial_highlights":"Impact on 2026 consolidated results: Unknown (Unknown)","jir_category":"","jir_hashtags":"#GNIGroup, #PrivateBrand, #MedTech, #NewProductAnnouncement","jir_key_figures":"FDA approval of Accelagen\u2122 Plus (510(k))\nU.S. sales start in Q1 2027\nMinor impact on 2026 consolidated results","jir_meta_title":"GNI Group Co., Ltd. Accelagen Plus FDA Approval Obtained | Targeting U.S. Sales in 2027","jir_meta_description":"GNI Group's consolidated subsidiary BAB has obtained FDA approval for Accelagen\u2122 Plus Surgical Matrix. This summarizes business strategy and financial impact regarding private-brand expansion in wound management and planned U.S. sales start in 2027.","jir_og_title":"FDA Approval for Accelagen Plus | MedTech Strategy Toward U.S. Launch","jir_og_description":"BAB has obtained FDA approval for Accelagen\u2122 Plus Surgical Matrix. This explains private-brand strengthening and plans for U.S. sales in 2027.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-110348","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n